Schnedar Bows Out of OC, Cosgrove Assumes Her Role

Cynthia Schnedar, director of CDER’s Office of Compliance, stepped down from her role on March 18 to take an unspecified private sector job, according to an email from CDER Director Janet Woodcock. Tom Cosgrove, who until recently served as director of the OC’s Office of Manufacturing Quality, assumed her position on April 4.

Woodcock said that Cosgrove “brings to the center’s leadership team a strong and proven background in drug quality and enforcement matters.”

Prior to heading the OMQ, Cosgrove led the OC’s Office of Unapproved Drugs and Labeling Compliance and worked in the Office of Chief Counsel as a litigator.

Francis Godwin, who most recently headed the Division of Drug Quality II within the OC, will serve as acting director of OMQ.

Stay up to date on regulatory stories like this one by subscribing to the Drug GMP Report. For over 20 years, drug manufacturers have relied on DGR for the latest on FDA’s interpretation and enforcement of cGMPs and the Quality Systems Regulation — information you need to stay in compliance.